Unveiling p65 as the target of diphyllin in ameliorating metabolic dysfunction-associated steatotic liver disease via targeted protein degradation technology
Our study presents diphyllin as a potential lead compound for MASLD therapy but also offers a novel approach for elucidating the mechanisms of action of natural products.
Authors
- Liangjie Wang (ORCID: https://orcid.org/0000-0003-3025-7459)
- Wenqian Cui
- Peng Chang (ORCID: https://orcid.org/0000-0001-7926-7725)
- Shuangcheng Chen
- Fengjing Xu
- Zhiying He (ORCID: https://orcid.org/0000-0002-0087-2277)
- Jinlong Li (ORCID: https://orcid.org/0000-0002-0915-4095)
- Mengyuan Liu (ORCID: https://orcid.org/0000-0001-7487-2897)
- Lei Zhang (ORCID: https://orcid.org/0009-0003-1693-0093)
- Xuejing Zhu (ORCID: https://orcid.org/0000-0001-7026-582X)
- Haowen Jiang
Institutions
- Chinese Academy of Sciences (CN)
- Nantong University (CN)
- Shanghai Institute of Materia Medica (CN)
- Nantong Science and Technology Bureau (CN)
- Shanghai East Hospital (CN)
- Shanghai Cell Therapy Research Institute (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-28
- DOI
- https://doi.org/10.3389/fphar.2025.1567639
- Citations
- 2
- Primary Topic
- Endoplasmic Reticulum Stress and Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.30
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Science and Technology Commission of Shanghai Municipality
- National Key Research and Development Program of China